Target cell specific antibody based photosensitizers for photodynamic therapy

Lauren T. Rosenblum; Makoto Mitsunaga; John W. Kakareka; Nicole Y. Morgan; Thomas J. Pohida; Peter L. Choyke; Hisataka Kobayashi

doi:10.1117/12.873887

4 February 2011 Target cell specific antibody-based photosensitizers for photodynamic therapy

Lauren T. Rosenblum, Makoto Mitsunaga, John W. Kakareka, Nicole Y. Morgan, Thomas J. Pohida, Peter L. Choyke, Hisataka Kobayashi

Author Affiliations +

Proceedings Volume 7910, Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications III; 791008 (2011) https://doi.org/10.1117/12.873887
Event: SPIE BiOS, 2011, San Francisco, California, United States

Abstract

In photodynamic therapy (PDT), localized monochromatic light is used to activate targeted photosensitizers (PS) to induce cellular damage through the generation of cytotoxic species such as singlet oxygen. While first-generation PS passively targeted malignancies, a variety of targeting mechanisms have since been studied, including specifically activatable agents. Antibody internalization has previously been employed as a fluorescence activation system and could potentially enable similar activation of PS. TAMRA, Rhodamine-B and Rhodamine-6G were conjugated to trastuzumab (brand name Herceptin), a humanized monoclonal antibody with specificity for the human epidermal growth factor receptor 2 (HER2), to create quenched PS (Tra-TAM, Tra-RhoB, and Tra-Rho6G). Specific PDT with Tra-TAM and Tra-Rho6G, which formed covalently bound H-dimers, was demonstrated in HER2+ cells: Minimal cell death (<6%) was observed in all treatments of the HER2- cell line (BALB/3T3) and in treatments the HER2+ cell line (3T3/HER2) with light or trastuzumab only. There was significant light-induced cell death in HER2 expressing cells using Tra-TAM (3% dead without light, 20% at 50 J/cm², 46% at 100 J/cm²) and Tra-Rho6G (5% dead without light, 22% at 50 J/cm², 46% at 100 J/cm²). No efficacy was observed in treatment with Tra-RhoB, which was also non-specifically taken up by BALB/3T3 cells and which had weaker PS-antibody interactions (as demonstrated by visualization of protein and fluorescence on SDS-PAGE).

Citation Download Citation

Lauren T. Rosenblum, Makoto Mitsunaga, John W. Kakareka, Nicole Y. Morgan, Thomas J. Pohida, Peter L. Choyke, and Hisataka Kobayashi "Target cell specific antibody-based photosensitizers for photodynamic therapy", Proc. SPIE 7910, Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications III, 791008 (4 February 2011); https://doi.org/10.1117/12.873887

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
7 PAGES

DOWNLOAD PAPER SAVE TO MY LIBRARY

GET CITATION

RIGHTS & PERMISSIONS

Get copyright permission Get copyright permission on Copyright Marketplace

KEYWORDS

Picosecond phenomena

Luminescence

Photodynamic therapy

Photosensitizer targeting

Cancer

Cell death

Rhodamine B

Show All Keywords

Keywords/Phrases

Search In:

Publication Years